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BACKGROUND: Cognitive dysfunction is a core feature of depression and tends to persist even after mood
symptoms recover, leading to detrimental effects on clinical and functional outcomes. However, most currently
available treatments have not typically addressed cognition. Modaﬁnil has been shown to have beneﬁcial effects on
cognitive function and therefore has the potential to improve cognition in depression. The objective of this double-
blind, placebo-controlled study was to investigate the effects of modaﬁnil on cognitive functions in patients with
remitted depression.
METHODS: In total, 60 patients with remitted depression participated in the study. Cognitive functions were
evaluated with tests of working memory, planning, attention, and episodic memory from the Cambridge Neuro-
psychological Test Automated Battery at the baseline session and after treatment. A double-blind, randomized,
placebo-controlled, parallel groups design was used to assess the effects of single-dose (200 mg) modaﬁnil (n 5 30)
or placebo (n 5 30) on cognition and fatigue. The main outcome measures were neurocognitive test scores from the
Cambridge Neuropsychological Test Automated Battery. Visual analogue scales for subjective feelings and fatigue
were used as secondary measures.
RESULTS: The modaﬁnil group had signiﬁcantly better performance on tests of episodic memory (p 5 .01, ηp2 5 .10)
and working memory (p 5 .04, ηp2 5 .06). Modaﬁnil did not improve planning or sustained attention.
CONCLUSIONS: This study suggested that modaﬁnil (200 mg) could improve episodic memory and working
memory performance in patients with remitted depression. Modaﬁnil may have potential as a therapeutic agent to
help remitted depressed patients with persistent cognitive difﬁculties.
Keywords: Cognition, Cognitive enhancer, Depression, Memory, Modaﬁnil, TreatmentISShttp://dx.doi.org/10.1016/j.bpsc.2016.11.009Cognitive dysfunction is a core feature of depression. Cogni-
tive symptoms are among the most frequently endorsed
symptoms, and nearly half of the patients continue to report
residual cognitive symptoms between episodes (1). Cognitive
dysfunction has been shown to be associated with poorer
functional outcomes (2,3) and higher rates of relapse (4) in
patients with depression. However, there are major challenges
to addressing the impact of cognitive problems in depression.
First, clinical practitioners tend to inquire about and treat the
mood symptoms and frequently do not ask patients about
cognitive problems (5). Second, when measured, the effects
on cognition of most currently available treatments for depres-
sion are relatively small (6). Recently, cognitive dysfunction has
been increasingly recognized as a novel target for treatment in
depression (7). Alternative therapeutic interventions are needed
to tackle cognitive problems in depression. In this double-
blind, randomized, placebo-controlled study, we investigated& 2017 Society of Biological Psychiatry. Pub
N: 2451-9022 Biological Psychiatry: Cognitive Neur
SEE COMMENTAthe effects of single-dose modaﬁnil on cognitive domains in
patients with remitted depression.
Modaﬁnil is a wake-promoting agent currently licensed for
narcolepsy and shift work sleep disorder (8). Its beneﬁcial
effects on sleep problems, fatigue, and motivation have led to
its use to alleviate symptoms in patients with depression.
A meta-analysis of randomized placebo-controlled trials
revealed that modaﬁnil augmentation was associated with
greater reduction in symptom severity in depression (9).
Notably, modaﬁnil’s effectiveness was evident in the ﬁrst
week, suggesting possible acute or subchronic effects. How-
ever, there was not a single cognitive outcome in the
previously published controlled studies. To date, only one
open-label study has measured cognitive performance and
demonstrated improvement with modaﬁnil augmentation in an
executive function task (10). Over the past 2 decades, the
cognition-enhancing potential of modaﬁnil has been shown forlished by Elsevier Inc. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/). 1
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CNNI Modaﬁnil in Remitted Depressionvarious domains of cognitive performance in healthy volun-
teers (11–13). Modaﬁnil also improved cognitive dysfunction in
other psychiatric conditions, including attention-deﬁcit/hyper-
activity disorder (14) and schizophrenia (15). Procognitive
effects of modaﬁnil on working memory were associated with
its effects on noradrenaline and dopamine in the prefrontal
cortex. It was suggested that modaﬁnil’s action on glutama-
tergic pathways may be linked with positive effects on
encoding (15).
A growing body of evidence indicates that cognitive deﬁcits
in depression are seen even after mood symptoms recover
(16,17). A recent meta-analysis of depression studies examin-
ing a broad range of cognitive domains showed that the
magnitude of cognitive deﬁcits in remitted depression were in
some domains comparable to deﬁcits during episodes (18).
Patients with remitted depression showed cognitive deﬁcits in
the domains of executive function, memory, and attention.
Given these previously published ﬁndings, we speciﬁcally
aimed to recruit patients with remitted depression to test the
efﬁcacy of modaﬁnil on cognition. Using patients in remission
minimizes the confounding effects of depressed mood on
cognition. Neuropsychological performance in depression is
highly heterogeneous (17,18); therefore, differences between
patients in cognitive deﬁcits should be taken into consider-
ation. In this study, we used a baseline cognitive testing
session to assess possible performance differences within the
sample. The rationale for test selection was based on those
tests shown to be most affected in the recent meta-analysis
(18). Measures from this session were used to inform analyses
at the intervention session.
The main aim of this study was to investigate whether a
single dose of modaﬁnil (200 mg) could improve performance
on cognitive tests in patients with remitted depression. The
possible mediating role of clinical variables on cognition was
assessed, including fatigue symptoms, psychosocial function-
ing, and work functioning.METHODS AND MATERIALS
Research Governance
The study was jointly sponsored by the University of Cam-
bridge and Cambridgeshire and Peterborough National Health
Service (NHS) Foundation Trust. The protocol was submitted
to Medicines and Health Products Regulatory Agency, and the
study was classiﬁed as not a clinical trial of an investigational
medicinal product. Study funding was from a core award to
the Behavioural and Clinical Neuroscience Institute from the
Medical Research Council and the Wellcome Trust. The Ethics
application was approved on June 25, 2014, by the NHS
National Research Ethics Service–Cambridge East Research
Ethics Committee (Ethics Reference No. 14/EE/0178). The
study was adopted by National Institute of Health Research
Clinical Research Network–Mental Health and registered into a
public database (UK CRN ID: 17355) that was accessible
online. The consent procedure was in line with NHS National
Research Ethics Service ethical standards and was compliant
with the Declaration of Helsinki. Written informed consents
were obtained at the baseline session.2 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ] 20Participants
In total, 60 patients with remitted depression aged between 18
and 65 years were recruited from a range of mental health
trusts, from general practitioner surgeries, and through online
and local advertisements. Inclusion criteria were 1) conﬁrmed
diagnosis of a previous unipolar depressive episode (during
the last 3 years) according to ICD-10 diagnostic criteria, 2)
currently in remission from depression (score of less than
12 on the Montgomery–Åsberg Depression Rating Scale
[MADRS]) for at least 2 months, and 3) ﬂuency in English.
Exclusion criteria were 1) history of head injury, 2) mental
retardation, 3) any other psychiatric diagnosis (except comor-
bid anxiety), 4) active suicidal ideation, 5) cognitive disorder
owing to a medical condition, 6) pregnancy and breastfeeding,
7) treatment-resistant hypertension or any known signiﬁcant
cardiovascular disease, 8) renal or liver disease/impairment, 9)
taking hormonal contraceptives, anticonvulsants, or warfarin, 10)
taking drugs that are metabolized through CYPC19 enzymes or
drugs that are eliminated by gastrointestinal CYP3A enzymes,
and 11) taking maximum dose of antidepressant medication that
is metabolized through CYP2D6 enzymes owing to a possible
interaction in people who have low metabolizer status (approx-
imately 7% of the U.K. population).
The sample consisted of 37 female and 23 male patients.
The mean age of participants was 45.03 6 10.82 years, the
mean length of current remission was 8.21 6 7.49 months,
and the mean number of previous depressive episodes was
3.18 6 1.52. Patients had some degree of residual depressive
symptoms; the mean MADRS score at the baseline session
was 5.33 6 3.25. The details of demographic and clinical
features are presented in Table 1. The groups were balanced in
terms of age, gender, and education levels (Table 1). Of the
sample, 48 patients were on antidepressant medication (citalo-
pram 5 15, venlafaxine 5 11, sertraline 5 6, ﬂuoxetine 5 5,
duloxetine 5 2, mirtazapine 5 2, dosulepin 5 2, doxapin 5 1,
bupropion 5 1, nortryptiline, 5 1, amitryptiline, 5 1, trazodone 5
1), whereas 12 patients were unmedicated. The study sessions
were conducted between November 2014 and November 2015.
Study Sessions
Baseline Session. Participants attended a baseline session
at their local mental health trust. They were assessed at the
same time interval (10 AM to 2 PM) in a quiet room, and they
were advised not to take caffeinated drinks at least 2 hours
before the session. Benzodiazepine use was not allowed prior
to the session. The session involved detailed evaluation of
clinical features, depression history, anxiety ratings (State and
Trait Anxiety Inventory), depressive symptom severity rating
with MADRS, premorbid IQ (National Adult Reading Test),
psychosocial functioning (Global Assessment of Functioning),
work functioning (Lam Employment Absence and Productivity
Scale), and computerized cognitive testing. The following tests
from the Cambridge Neuropsychological Test Automated
Battery (CANTAB) were used: 1) Rapid Visual Information
Processing (RVIP), 2) Stockings of Cambridge (SOC), 3)
Spatial Working Memory (SWM), and 4) Paired Associates
Learning (PAL). A summary of the tests, including descriptions,
main outcome measures, and references, is presented in
Table 2 (19–23). Detailed descriptions can be found in the17; ]:]]]–]]] www.sobp.org/BPCNNI
Table 1. Demographic and Clinical Characteristics of Groups
Modaﬁnil (n 5 30) (Mean 6 SD) Placebo (n 5 30) (Mean 6 SD) F Value p Value
Age, Years 43.97 6 11.03 46.10 6 10.69 0.578 .45
Premorbid IQ (NART) 116.6 6 4.69 117.57 6 4.81 0.620 .43
Education, Years 13.96 6 2.98 14.06 6 2.55 0.019 .89
MADRS (Drug Session) 4.6 6 2.72 4.5 6 3.24 0.017 .89
Number of Episodes 3.1 6 1.49 3.26 6 1.57 0.177 .67
Remission, Months 7.44 6 6.82 9.06 6 8.22 0.768 .38
Age at First Episode, Years 26.96 6 12.5 29.2 6 13.01 0.460 .50
Length of First Episode, Months 12.1 6 7.19 10.43 6 5.12 1.068 .30
Psychosocial Functioning (GAF) 71.03 6 8.56 70.93 6 7.23 0.002 .96
Work Functioning (LEAPS) 8.52 6 5.30 7.38 6 6.15 0.269 .60
State Anxiety 38.43 6 10.29 36.7 6 12.45 0.345 .55
Trait Anxiety 48.1 6 9.84 47.36 6 13.98 0.055 .81
Fatigue Severity Scale 4.72 6 1.37 4.41 6 1.39 0.770 .38
Gender, % Female 63.3 60 χ2 5 0.071 .79
Medication Status, % Medicated 86.6 73.3 χ2 5 1.667 .19
GAF, Global Assessment of Functioning; LEAPS, Lam Employment Absence and Productivity Scale; MADRS, Montgomery–Åsberg Depression
Rating Scale; NART, National Adult Reading Test.
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providing baseline data, this session familiarized participants
with the tests.
Intervention Session. Approximately 1 week after the
baseline session, participants attended the intervention ses-
sion at the National Institute of Health Research/Wellcome
Trust Clinical Research Facility at Addenbrooke’s Hospital. A
double-blind, randomized, placebo-controlled parallel groups
design was used. Study sessions were scheduled at the same
time of the day (10 AM to 12 PM) to keep the testing time
standard. Before dosing, participants had their current mental
state assessed as well as a baseline blood pressure, electro-
cardiogram, urine drug screening, and assessment of breath
alcohol concentration. The assessments included the Fatigue
Severity Scale, visual analogue scales of feelings, anxiety
ratings (State and Trait Anxiety Inventory), and depressive
symptom ratings (MADRS). After the assessments, partici-
pants received modaﬁnil (200 mg) or placebo. The modaﬁnil
dose was selected on the basis of previous experimental
studies that reported procognitive effects (12,14). Cognitive
testing started 2 hours after dosing. Modaﬁnil was shown to
reach its peak level in 2 to 4 hours, so the interval allowed us
to test the participants in a time window while modaﬁnil had
peak plasma levels. Blood pressure and heart rate were
monitored every half hour after dosing. The participants spent
2 hours before the test administration in a quiet day room at
the Clinical Research Facility. All neuropsychological tests
were delivered by the ﬁrst author, who is a trained psychiatrist.
Light lunches and snacks were provided with the exception of
caffeinated drinks.
At the intervention session, the CANTAB SWM task with
high levels of difﬁculty (up to 12 boxes) and the PAL test with
high levels of difﬁculty (up to 12 shapes) were administered.
One Touch Stockings (OTS), a challenging planning task, was
selected instead of the easier planning task, the SOC. Those
versions of the tasks in previously published studies have
been found to have greater sensitivity and to avoid ceilingBiological Psychiatry: Cognitive Neuroscieneffects. The version of CANTAB RVIP used was the same in
both sessions. Primary and secondary cognitive measures are
listed in Table 2.
Statistical Analysis
The data were analyzed with version 21.0 of the SPSS
statistical software package (IBM Corp., Armonk, NY). Sepa-
rate linear models were constructed for each neuropsycho-
logical outcome at the intervention session as dependent
variables. The groups (modaﬁnil and placebo) were ﬁxed
factors, and neuropsychological test scores at the baseline
were used as covariates to account for within-group variance
in preexisting cognitive performance. In the intervention ses-
sion, test versions with higher difﬁculty levels were used to
minimize learning effects. The statistical approach allowed us
to account for the cognitive level at baseline on performance
after the intervention without potential confounding effects
related to differential task difﬁculty. Additional covariates
(National Adult Reading Test, age, etc.) were selected if they
accounted for a signiﬁcant proportion of the variance in linear
models. Sidak correction was applied for adjustment of multi-
ple comparisons. All p values reported are corrected for
multiple comparisons. Estimates of effect sizes are reported
as partial eta squared (ηp2) values. Qualitative interpretations
of effect sizes as small, medium, and large correspond to ηp2
values of .001, .059, and .138, respectively (25).RESULTS
Randomization
Modaﬁnil and placebo groups were well matched in terms of
age, gender, premorbid IQ, depressive symptom scores,
anxiety levels, clinical features, fatigue severity, psychosocial
functioning, and work functioning (Table 1). Baseline cognitive
test measures were comparable between the two groups
(Supplemental Table S1). The numbers of unmedicated
participants were comparable between groups (χ2 5 1.667,ce and Neuroimaging ] 2017; ]:]]]–]]] www.sobp.org/BPCNNI 3
Table 2. Brief Descriptions and Main Measures of the Neurocognitive Tasks Used
Cognitive Task Description Reference Main Measures
Rapid Visual Information
Processing
A test of sustained attention that requires detection of infrequent
three-digit sequences among serially presented digits
Park et al. (19) Primary:
- RVIP A0 (target sensitivity)
Secondary:
- RVIP B0 0 (response bias)
- Mean latency
Stockings of Cambridge A spatial planning task involving planning a sequence of moves
to achieve the same arrangement with the target pattern
Shallice (20)
Owen et al. (22)
Primary:
- Mean moves (n moves)
Secondary:
- Mean initial thinking time
(n moves)
- Problems solved in minimum
moves
One Touch Stockings Similar to Stockings of Cambridge, but the number of moves
required to match the target pattern is required without moving
the balls
Owen et al. (21)
Müller et al. (12)
Primary:
- Mean choices to correct
Secondary:
- Mean latency to correct
- Problems solved in ﬁrst choice
Spatial Working Memory A test of spatial working memory to ﬁnd hidden “blue tokens”
without returning to a box where one has previously found
(up to 8 boxes); version with high difﬁculty levels is up to
12 boxes
Owen et al. (22) Primary:
- Between search errors (total)
- Between search errors (n boxes)
- Strategy
Paired Associates
Learning
A test of the ability to form visuospatial associations and the
number of reminder presentations required to learn all the
associations (up to 8 shapes); version with high difﬁculty
levels is up to 12 shapes
Sahakian et al. (23) Primary:
- Total errors adjusted (all shapes)
- Total errors adjusted (n shapes)
Secondary:
- First trial memory score
- Mean errors to success
- Mean trials to success
RVIP, Rapid Visual Information Processing.
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CNNI Modaﬁnil in Remitted Depressionp 5 .19 [two sided]). The participants were asked at the end of
the test session whether they thought they were on modaﬁnil or
placebo. In response, 40% of patients in the modaﬁnil group
were able to guess that they received modaﬁnil, whereas 26.6%
of patients in the placebo group correctly guessed that they
received placebo. Comparison of the two groups showed no
signiﬁcant difference in the ability to correctly detect group
membership (χ2 5 1.200, p 5 .27 [two sided]). The ability to
guess the correct allocation was at chance level.
Effects of Modaﬁnil on Physiological and Subjective
Measures
Modaﬁnil had no effect on visual analogue scales of fatigue
(F 5 3.595, p 5 .06, ηp2 5 .05). Similarly, self-reported feelings
for 15 dimensions (e.g., alert vs. drowsy, strong vs. feeble) as
measured by visual analogue scales were not signiﬁcantly
different between groups (F values ranging between 0.004 and
1.459, p values ranging between .26 and .95).
Heart rate increased over time (F5 6.620, p5 .01, ηp25 .10),
but there was no main effect of modaﬁnil (F 5 0.84, p 5 .46,
ηp2 5 .01). Over time, there was a signiﬁcant decrease in
systolic pressure (F 5 2.935, p 5 .03, ηp2 5 .04), whereas
the decrease in diastolic pressure was not signiﬁcant
(F 5 2.051, p 5 .08, ηp2 5 .03). There was no effect of
modaﬁnil on systolic (F 5 0.790, p 5 .49, ηp2 5 .01) or4 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ] 20diastolic (F 5 1.496, p 5 .20, ηp2 5 .02) pressure changes.
None of the participants had signiﬁcant adverse events during
participation or within 24 hours after the study, conﬁrmed by a
follow-up telephone call. In total, 10 patients reported mild
side effects: headache (placebo 5 1, modaﬁnil 5 1), increased
anxiety (placebo 5 1, modaﬁnil 5 1), drowsiness (modaﬁnil 5
2), blurred vision (placebo 5 2), sleep disturbance on the night
of the study session (modaﬁnil 5 2). Incidence of mild side
effects was not signiﬁcantly different between groups.
Effects of Modaﬁnil on Neurocognitive Testing
Episodic Memory (PAL). Modaﬁnil signiﬁcantly improved
performance as measured by fewer errors on the PAL test (F 5
6.199, p 5 .01, ηp2 5 .10) (Figure 1). In addition to the total
number of errors, four secondary measures of errors were
assessed for PAL performance. The modaﬁnil group had fewer
errors on PAL mean errors to success (F 5 9.935, p , .01, ηp2
5 .26) (Table 3). Modaﬁnil had marginal effects on ﬁrst trial
memory score (F 5 3.883, p 5 .054, ηp2 5 .06) and on mean
trials to success (F 5 3.771, p 5 .057, ηp2 5 .06). To assess
whether the effect of modaﬁnil was on encoding or learning, a
repeated measures analysis of variance was conducted based
on the number of trials to solve the PAL 12 shapes problem.
The main effect of learning was not signiﬁcant for modaﬁnil
(F 5 1.576, p 5 .20, ηp2 5 .03).17; ]:]]]–]]] www.sobp.org/BPCNNI
Figure 1. (Left) Episodic memory performance according to the difﬁculty level is shown. The repeated measures analysis of variance, which controlled for
baseline performance, demonstrated a main effect of modaﬁnil (F 5 6.199, p 5 .01, ηp2 5 .10). (Right) The bar graph shows a signiﬁcant difference between
modaﬁnil and placebo groups at the Paired Associates Learning (PAL) 12 shapes stage after controlling for baseline performance (F 5 4.211, p 5 .02,
ηp2 5 .13).
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a trend for fewer errors overall on the SWM task (F 5 3.023,
p 5 .08, ηp2 5 .05). When means plot (Figure 2) was explored,
there was a marked difference at the 12 boxes stage. Analysis
of covariance revealed that patients in the modaﬁnil group had
fewer errors in the 12 boxes stage of the SWM test (F 5 4.125,
p 5 .04, ηp2 5 .06) (Figure 2). The strategy score was not
signiﬁcantly different (F 5 0.984, p 5 .32, ηp2 5 .01) (Table 3).Planning (One Touch SOC). There was no effect of
modaﬁnil on planning performance (F 5 1.057, p 5 .37,
ηp2 5 .01). Modaﬁnil did not have a signiﬁcant effect on the
number of problems solved in minimum moves (F 5 1.744,Table 3. Cognitive Test Results at the Intervention Session
Modaﬁnil (n 5 30) (Mean 6 SD)
PAL Total Errors Adjusteda 29.97 6 34.95
PAL Total Errors Adjusted (12 Shapes) 13.90 6 20.15
PAL First Trial Memory Score 26.10 6 7.29
PAL Mean Errors to Success 5.67 6 5.35
PAL Mean Trials to Success 2.72 6 1.20
SWM Between Errorsa 100.17 6 62.74
SWM Between Errors (12 Boxes) 44.40 6 29.41
SWM Strategy 53.63 6 17.56
OTS Problems Solved on First Choice 9.40 6 2.40
OTS Mean Choices to Correcta 1.63 6 0.40
OTS Mean Latency to Correct (ms) 29632.57 6 20967.91
RVIP A0 (Target Sensitivity) 0.919 6 0.05
RVIP B0 0 (Response Bias) 0.843 6 0.36
RVIP Mean Latency (ms) 469.48 6 86.40
OTS, One Touch Stockings; PAL, Paired Associates Learning; RVIP, Ra
Statistical values were obtained via general linear model–analysis of co
aFor these measures, repeated measures ANCOVA was used with difﬁ
covariate. For other measures, univariate ANCOVA with relevant covariat
participants in each group due to loss of data related to technical problem
Biological Psychiatry: Cognitive Neuroscienp 5 .19, ηp2 5 .03). The modaﬁnil group had longer mean
latencies to make a decision, although this difference was not
signiﬁcant (F 5 1.198, p 5 .27, ηp2 5 .02) (Table 3).
Attention (RVIP). There was no signiﬁcant effect of mod-
aﬁnil on target sensitivity index, RVIP A0 (F 5 1.544, p 5 .21,
ηp2 5 .02), and response bias, RVIP B0 0 (F 5 0.127, p 5 .12,
ηp2 , .01). RVIP mean latency was not signiﬁcantly different
across groups (F 5 2.208, p 5 .14, ηp2 5 .03) (Table 3).
There was no signiﬁcant effect of age, subsyndromal
depressive symptoms, or anxiety scores on any of the
cognitive measures reported. There were no differential effects
of gender on cognitive test measures.Placebo (n 5 30) (Mean 6 SD) F Value p Value ηp2
50.10 6 49.90 6.199 .01 .10
30.28 6 35.43 4.211 .01 .11
23.52 6 6.89 3.883 .054 .06
8.04 6 6.31 9.935 ,.01 .26
3.29 6 1.63 3.771 .057 .06
102.47 6 51.74 3.023 .08 .05
48.43 6 22.91 4.125 .04 .06
52.90 6 17.42 0.984 .32 .01
10.07 6 2.13 1.744 .19 .03
1.53 6 0.32 1.057 .37 .01
21693.82 6 10171.27 1.198 .27 .02
0.940 6 0.04 1.544 .21 .02
0.818 6 0.39 0.127 .12 ,.01
426.27 6 77.87 2.208 .14 .03
pid Visual Information Processing; SWM, Spatial Working Memory.
variance (ANCOVA).
culty as the factor and relevant cognitive test scores at baseline as
es from baseline session were used. PAL test results were from 29
s.
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Figure 2. (Left) Working memory performance according to the difﬁculty level is shown. Repeated measures analysis of variance, which controlled for
baseline performance, showed a trend effect of modaﬁnil (F 5 3.023, p 5 .08, ηp2 5 .05). (Right) The bar graph shows a signiﬁcant difference between
modaﬁnil and placebo groups at the Spatial Working Memory (SWM) 12 boxes stage after controlling for baseline performance (F 5 4.125, p 5 .04, ηp2 5 .06).
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The associations between cognitive functions at baseline and
clinical features, as well as measures of functionality, were
investigated using bivariate correlation analyses. Depressive
symptom severity was signiﬁcantly associated with longer
response latency on the RVIP test (Spearman’s ρ 5 .33,
p , .01 [two tailed]). Other cognitive tests were not associated
with residual depressive symptoms. Age at onset, number of
previous episodes, and duration of remission were not sig-
niﬁcantly associated with cognitive test measures.
Psychosocial functioning (Global Assessment of Function-
ing) was signiﬁcantly associated with working memory per-
formance (SWM between errors) (ρ 5 2.31, p 5 .01 [two
tailed]) and attention performance (RVIP A0) (ρ 5 .35, p , .01
[two tailed]). Work functioning (Lam Employment Absence and
Productivity Scale) was not associated with cognitive test
performance.
Signiﬁcant associations were found between baseline cog-
nitive testing and cognitive performance at the intervention
session. The correlation coefﬁcients and signiﬁcance levels
were as follows: baseline PAL total errors adjusted 2 inter-
vention PAL total errors adjusted (ρ 5 .74, p , .001); baseline
SWM between search errors 2 intervention SWM between
search errors (ρ 5 .74, p , .001); baseline RVIP A0 2
intervention RVIP A0 (ρ 5 .73, p , .001); baseline SOC mean
moves 2 intervention OTS mean choices to correct (ρ 5 .48,
p 5 .001).
DISCUSSION
This double-blind, placebo-controlled, proof-of-concept study
in patients with remitted depression suggested that modaﬁnil
could improve performance on episodic memory and working
memory tests. However, there were no effects on attention
and planning. It has been reported that modaﬁnil can improve
forms of cognition in both healthy volunteers and people with
cognitive impairment owing to psychiatric conditions (11–15).
Findings from the current study indicate that modaﬁnil can
also improve domains of cognition in those with remitted6 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ] 20depression. To our knowledge, this study is the ﬁrst to
investigate the effects of modaﬁnil in remitted depression.
The effects of modaﬁnil on episodic memory were found to
be within the medium to large effect size range. In contrast,
previous studies did not ﬁnd an improvement in episodic
memory with single-dose modaﬁnil (11,12,14), although most
of these studies used an easier version of the PAL test. The
only study that used the new difﬁcult version of the PAL test,
which was up to the 12 shapes level (12), reported possible
ceiling effects in their high-functioning healthy sample. An
alternative explanation for the improvement by modaﬁnil in
episodic memory might be related to a possibly altered neural
circuit in patients with remitted depression. One of the
proposed neural mechanisms for cognitive dysfunction in
depression is impaired hippocampal function. This was sup-
ported by consistent ﬁndings of reduced hippocampal vol-
umes in people with a history of depression (26,27). Patients
with depression showed lower hippocampal activation in
functional imaging during an associative learning task (28).
The ﬁndings from the current study indicated that the effects
of modaﬁnil were related to improvements at the initial
encoding stage rather than on the subsequent learning trials
of the PAL task. In a previously published imaging study by
our group, we demonstrated that the hippocampal formation
was primarily recruited in the encoding stage of the PAL task,
whereas parahippocampal structures were more activated in
retrieval (29). The activation was also associated with increas-
ing task difﬁculty. Episodic memory improvement observed in
this study could be associated with neurochemical changes
induced by modaﬁnil in hippocampal areas, particularly via
glutamatergic mechanisms. Experimental studies indicate that
modaﬁnil could induce glutamate release in the hippocampus
(30). Modaﬁnil was shown to increase regional blood ﬂow to
the hippocampus in healthy volunteers (31); therefore, this may
be the underlying mechanism of improved performance in the
PAL test.
The ﬁnding of working memory improvements at the high-
est level of difﬁculty was similar to that seen in a study of
healthy volunteers that used the high-functioning version of17; ]:]]]–]]] www.sobp.org/BPCNNI
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of the CANTAB SWM task did not show signiﬁcant effects of
modaﬁnil, again probably related to ceiling effects. The effects
of modaﬁnil were evident only in the 12 boxes stage of SWM in
the current study. Previously, single-dose modaﬁnil (200 mg)
was shown to improve working memory and altered frontal
activation in sleep-deprived healthy volunteers (32). In patients
with schizophrenia, modaﬁnil administration was associated
with increased dorsolateral prefrontal activity (33). The actions
of modaﬁnil on norepinephrine and dopamine in dorsolateral
prefrontal regions likely play a role in improved working
memory performance (34,35). It should also be noted that
working memory performance at baseline was associated with
psychosocial functioning as measured by the Global Assess-
ment of Functioning in our sample of remitted depressed
patients. This ﬁnding suggested that working memory is a
particularly critical domain for future studies as a potential
target to improve daily functioning (36).
Previous studies consistently reported improvements in
planning accuracy with single-dose modaﬁnil in healthy vol-
unteers (10–14). However, modaﬁnil did not have a signiﬁcant
effect on planning accuracy or speed in the current study. The
effects of modaﬁnil on OTS latency varied across studies.
Mean latency scores in the OTS in this study were noteworthy
because both groups took markedly longer times to correction
compared with those in previous studies (37,38). The lack of
improvement in RVIP performance was in line with previous
studies using single-dose modaﬁnil (10–14). This study lends
further support to the conclusion that modaﬁnil does not exert
its effects on domains of memory and executive function via
enhancing attention.
There are several limitations to the current study. First, this
study investigated the acute effects rather than long-term
effects of modaﬁnil. Second, the majority of participants were
on regular antidepressant treatment. However, our study
accurately reﬂects the clinical population. The unmedicated
group and patients on speciﬁc types of antidepressants (e.g.,
selective serotonin reuptake inhibitor, serotonin and norepi-
nephrine reuptake inhibitor) were not sufﬁciently large to run
separate analyses. Third, there was not a measure for
subjective cognitive complaints, although it appears that
subjective measures are more closely related to the mood
symptoms (39). The diagnoses were made on the basis of
clinical evaluation and previous clinical records, but a struc-
tured interview (Schedules for Clinical Assessment in Neuro-
psychiatry) for ICD-10 diagnoses was not used. Last, this
proof-of-concept study investigated the cognitive effects of
modaﬁnil on a number of domains, and the ﬁndings were
preliminary for future research.
Despite the growing evidence that cognitive dysfunction in
depression extends beyond the episodes, few studies have
sought to examine potential therapeutic interventions to
address those problems. Those including cognitive outcomes
currently focused on treatment of acute episodes along with
cognitive deﬁcits (40). Cognitive deﬁcits in remitted depression
have detrimental effects on life functioning and pose a risk for
relapse. Recurrent depression has been reported to increase
the risk for dementia (41). Recently, achievement of “cognitive
remission” has been proposed as a novel objective for treat-
ment of depression (42,43). Modaﬁnil has been used in variousBiological Psychiatry: Cognitive Neuroscienclinical populations, including depression. Augmentation with
modaﬁnil could be a safe and effective option for acute
depressive episodes (9). This proof-of-concept study sug-
gested that modaﬁnil could improve episodic and working
memory functions in remitted depressed patients. Further
research into the use of modaﬁnil over a longer time period,
and in combination with psychological treatments on cognitive
dysfunction in depression, is warranted.ACKNOWLEDGMENTS AND DISCLOSURES
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